logo
episode-header-image
Sep 2023
56m 39s

2. The drug behind Europe's most valuabl...

Goalhanger
About this episode
How much harm has been done by decades of governments investing too little? Is buy-now-pay-later causing misery or joy for young shoppers? Are supermarkets cutting prices fast enough? Is Novo Nordisk’s anti obesity wonder drug Semaglutide the most important pharmaceutical discovery of the century? Join Robert and Steph as they answer all these questions and ... Show More
Up next
Oct 7
320. Can Britain lead the world in driverless cars?
Is Wayve the start-up that could at last be a British global AI giant? Why does its boss Alex Kendall think the UK is the best place to grow a tech business? How soon will most of us be riding in driverless taxis and cars? Robert talks to the founder and chief executive of Wayve, ... Show More
56m 42s
Oct 4
319. How to fill the Chancellor’s hole, with Dan Neidle
Is a Smorgasbord of tax rises the best way to raise money? Should the capital gains tax rate be aligned with income tax? What about increased taxes on banks? Dan Neidle is back to tell Robert and Steph what he’d do in the upcoming Budget. Plus, how Reeves was punished by the ONS’ ... Show More
37m 16s
Oct 1
318. What’s the cost of Andy Burnham's big plans?
Why was Burnham’s speech such an important economic and political reset? Is his promise of an NHS model for social care all it seems? Burnham has raised the possibility of rejoining the EU, but would European leaders welcome us back? Robert has been in Liverpool at Labour Confere ... Show More
35m 25s
Recommended Episodes
Dec 2024
068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More
11m 16s
Jun 2024
The Dark Story Behind Ozempic’s $500B Business Empire
Episode 601: Sam Parr ( https://twitter.com/theSamParr ) and Shaan Puri ( https://twitter.com/ShaanVP ) talk to Calley Means ( https://x.com/calleymeans ) about the $50T drug that has Americans in a chokehold.  — Show Notes: (0:00) Intro  (1:54) The problem with Ozempic (4:25) A ... Show More
1h 15m
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
<p>More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ... Show More
36m 59s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More
36m 59s
Oct 2021
Sick Money (Pt 1): Exposing the drug companies' price gouging tactics
In the first of two episodes this week, we're taking a deep dive into the pharmaceutical industry. How much does the medication you take actually cost? What if a company came along and bought the rights to a particular drug and started charging double, triple, or even 10,000 time ... Show More
29m 31s
Nov 2023
The $100 billion opportunity: How anti-obesity drugs are reshaping healthcare and consumer behavior
Goldman Sachs Research’s Chris Shibutani and Jason English explain the business and investor implications of the latest anti-obesity medications and their ripple effects in the healthcare industry and beyond. Learn more about your ad choices. Visit megaphone.fm/adchoices 
26m 30s
Mar 2025
The State of Weight-Loss Drugs
$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big- ... Show More
30m 7s
Oct 2024
Weight Loss Drug Ads: Good or Bad?
Companies are spending big bucks advertising weight-loss drugs like Ozempic and Rybelsus. This week, we’re dropping an episode of Brian Goldman’s White Coat, Black Art podcast into our feed.We thought you might find the topic interesting. In Canada, "reminder ads" can only give t ... Show More
27m 8s
Feb 2024
The obesity drug craze is entering its next phase
Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More
22m 46s